No wrongdoing: Bharat Biotech on row over Brazil Covaxin deal
Bharat Biotech on Wednesday denied reports of any wrongdoing in the Covaxin procurement deal in Brazil and said it followed a common, widely accepted, and established process that included an advance payment. The pharma company's response comes amid reports that Brazil is suspending its $324 million deal to procure indigenously developed Covaxin due to suspected irregularities.
admin 
Bharat Biotech on Wednesday denied reports of any wrongdoing in the Covaxin procurement deal in Brazil and said it followed a common, widely accepted, and established process that included an advance payment. The pharma company's response comes amid reports that Brazil is suspending its $324 million deal to procure indigenously developed Covaxin due to suspected irregularities.
